Targeted Oncology

Melphalan/HDS Shows Favorable Results in Patients with Low Hepatic Tumor Burden

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...
AlphaGalileo

A repurposed drug duo shows powerful synergy against liver fibrosis

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective ...
Le Lézard

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals, Inc. today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult ...
PharmiWeb

Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA

Expands Pain Management Portfolio with Next-Generation Topical NSAID TherapyRALEIGH, N.C.--(BUSINESS WIRE)--Acertis Pharmaceuticals, a specialty pharmaceutical company focused on delivering ...

Nitric Boost Ultra Formulation Analysis: Male Wellness Industry Enters 2026 With Growing Interest in Nitric Oxide Support Supplements

Industry Analysis Examines Eight-Ingredient Powdered Formula, Nitric Oxide Pathway Research, and Age-Specific Circulatory ...